1. FDA. Bioavailability and bioequivalence studies for orally administered drug products—general considerations: guidance for industry. Rockville: FDA, Center for Drug Evaluation and Research; 2003.
2. Nightingale SL (FDA Associate Commissioner for Health Affairs). Therapeutic equivalence of generic drugs—letter to health practitioners. January 28, 1998.
http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/AbbreviatedNewDrugApplicationANDAGenerics/ucm073182.htm
. Accessed 15 Feb 2012.
3. Kluznik JC, Walbek NH, Farnsworth MG, Melstrom K. Clinical effects of a randomized switch of patients from clozaril to generic clozapine. J Clin Psychiatry. 2001;62 Suppl 5:14–7.
4. Tothfalusi L, Speidl S, Endrenyi L. Exposure-response analysis reveals that clinically important toxicity difference can exist between bioequivalent carbamazepine tablets. Br J Clin Pharmacol. 2007;65:110–22.
5. Rosenthal J, Kong B, Jacobs L, et al. Did a switch to a generic antidepressant cause relapse? J Fam Pract. 2008;57:109–14.